Method for the selection of antibodies against BCMA
AssigneeEngmab SàRl
InventorsMinh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
Life of this patent
Estimating the term…
Abstract
An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent.
Claims5
A method of treating multiple myeloma (MM) comprising administering a bispecific antibody specifically binding to human B cell maturation factor (BCMA) and CD3 to a subject in need thereof, wherein
- c) said bispecific antibody comprises variable heavy and light chains of anti-CD3ϵ antibody SP34;
- and, wherein said bispecific antibody comprises variable heavy and light chains of an antibody specifically binding to BCMA wherein variable domain VH comprises the amino acid sequence of SEQ ID NO:59 and variable domain VL comprises the amino acid sequence of SEQ ID NO:89.
Dependencies are inferred from the claim text.